Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY)
(Delayed Data from OTC)
$24.40 USD
-0.15 (-0.61%)
Updated Aug 8, 2025 03:59 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Daiichi Sankyo Co., Ltd. - Sponsored ADR has a PEG ratio of 1.43 compared to the Medical - Drugs industry's PEG ratio of 1.26.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DSNKY 24.40 -0.15(-0.61%)
Will DSNKY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DSNKY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DSNKY
DSNKY vs. ZTS: Which Stock Is the Better Value Option?
TAK or DSNKY: Which Is the Better Value Stock Right Now?
DSNKY: What are Zacks experts saying now?
Zacks Private Portfolio Services
TAK vs. DSNKY: Which Stock Is the Better Value Option?
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?
TAK or DSNKY: Which Is the Better Value Stock Right Now?
Other News for DSNKY
Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript
Daiichi Sankyo reports Q1 results
Pfizer: Building The Next Oncology Empire
Why Novartis Is Still A 'Buy' After 15% Surge
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst